Review

The Treatment of Pulmonary Diseases and Respiratory-Related Conditions with Inhaled (Nebulized or Aerosolized) Glutathione

Jonathan Prousky¹,²

¹The Canadian College of Naturopathic Medicine, 1255 Sheppard Avenue East, Toronto, ON M2K 1E2, Canada and ²International Primary Health Care, The External Program, University of London, London, UK

Reduced glutathione or simply glutathione (γ-glutamylcysteinylglycine; GSH) is found in the cytosol of most cells of the body. GSH in the epithelial lining fluid (ELF) of the lower respiratory tract is thought to be the first line of defense against oxidative stress. Inhalation (nebulized or aerosolized) is the only known method that increases GSH’s levels in the ELF. A review of the literature was conducted to examine the clinical effectiveness of inhaled GSH as a treatment for various pulmonary diseases and respiratory-related conditions. This report also discusses clinical and theoretical indications for GSH inhalation, potential concerns with this treatment, its presumed mechanisms of action, optimal doses to be administered and other important details. Reasons for inhaled GSH’s effectiveness include its role as a potent antioxidant, and possibly improved oxygenation and host defenses. Theoretical uses of this treatment include Farmer’s lung, pre- and postexercise, multiple chemical sensitivity disorder and cigarette smoking. GSH inhalation should not be used as a treatment for primary lung cancer. Testing for sulfites in the urine is recommended prior to GSH inhalation. Minor side effects such as transient coughing and an unpleasant odor are common with this treatment. Major side effects such as bronchoconstriction have only occurred among asthma patients presumed to be sulfite-sensitive. The potential applications of inhaled GSH are numerous when one considers just how many pulmonary diseases and respiratory-related conditions are affected by deficient antioxidant status or an over production of oxidants, poor oxygenation and/or impaired host defenses. More studies are clearly warranted.

Keywords: aerosolized glutathione (GSH) – antioxidant – inhaled GSH – nebulized GSH – reduced GSH

Introduction

Reduced glutathione or simply glutathione (γ-glutamylcysteinylglycine; GSH) is found in the cytosol of most cells of the body (1). It is a tripeptide consisting of glycine, cysteine and glutamate. GSH functions in several enzyme systems within the body that assist with the quenching of free radicals and the detoxification of fat-soluble compounds (Table 1) (2–5). It also plays a significant metabolic role in supporting many different biochemical processes (e.g. amino acid transport, deoxyribonucleic acid synthesis and immune system augmentation) considered to be important mediators of health status (6).

Glutathione in the epithelial lining fluid (ELF) of the lower respiratory tract is thought to be the first line of defense against oxidative stress (6). The ELF concentration of GSH is 140 times that of serum concentrations with a redox ratio of >9:1 (7). In fact, alternations in alveolar and lung GSH metabolism are widely recognized as a central feature among many inflammatory lung diseases (8–14). In healthy lungs, the oxidant burden is balanced by local antioxidant defenses. However, in lung...
diseases cellular damage and injury is mediated by an increased oxidant burden and/or decreased antioxidant defenses.

In inflammatory lung diseases, supplementation with exogenous sources of GSH would be necessary to reduce the oxidant load and/or correct for antioxidant deficiencies within the lungs. A few published clinical studies have shown the oral administration of GSH to be ineffective at increasing plasma levels when given to healthy subjects (15), or when used for the treatment of hepatic cirrhosis (16). If the oral administration of GSH cannot raise plasma levels in healthy and diseased patients, it is doubtful that this method of delivery would have any appreciable effects at increasing GSH concentrations within the lungs.

Intravenous administration might be effective since it bypasses the gastrointestinal tract, immediately enters the blood stream, and presumably would saturate body tissues such as the lungs. Unfortunately, the results of a study did not show intravenous administration to be effective at increasing GSH levels within the ELF (17). When 600 mg of GSH was delivered intravenously to sheep, the levels in the venous plasma, lung lymph and ELF increased only for a very brief period of time. However, when the same amount of GSH was delivered through inhalation (nebulized or aerosolized), the baseline GSH level in the ELF (45.7 ± 10 μM) increased 7-fold at 30-min (337 ± 64 μM), remained above the baseline level 1 h later (P<0.001) and returned toward baseline levels by 2 h. Despite this short-term increase in GSH concentrations within the ELF, the inhalation method did not significantly increase the amount of GSH in the lung lymph, venous plasma and urine during the 2 h study period. The authors of this report concluded that inhalation specifically increased GSH levels at the lung epithelial surface.

Given that inhalation is the only known method that increases GSH levels in the ELF for a significant duration, a review of the literature was conducted to examine the clinical effectiveness of inhaled GSH as a treatment for various pulmonary diseases and respiratory-related conditions. Only reports involving human subjects were included in the analysis. The clinical and theoretical indications for GSH inhalation were summarized and potential concerns with this treatment reported. Other pertinent details such as its presumed mechanisms of action and optimal doses to be administered were compiled and evaluated.

Methods

Literature Search

Computer searches were conducted of English and non-English language articles in the Biomedical Reference Collection (1984 to August 2006), CINAHL (1982 to August 2006), MEDLINE (1965 to August 2006) and Nursing and Allied Health Collection (1985 to August 2006) databases. Articles were searched with the key search terms ‘Nebulized Glutathione,’ and ‘Glutathione’ in combination with ‘Aerosol’ OR ‘Inhalation.’ These keywords were also searched with words related to pulmonary and/or respiratory disease. To supplement the search, references of the articles found from the initial search were reviewed. Hand searching of relevant journals was also completed as part of the search.

Selection of Articles

To be included in the final review, articles had to report on the use and administration of inhaled GSH for pulmonary diseases and respiratory-related conditions in human subjects. Only peer-reviewed articles were reviewed.

Quality Assessment

An evidence grade was determined for each article. These evidence grades were adapted from the hierarchy of evidence developed by the Oxford Centre of Evidence Based Medicine (Table 2) (18).

| Enzyme system                        | Function                                                                 |
|--------------------------------------|--------------------------------------------------------------------------|
| Glutathione synthetase               | Gamma-glutamyl cycle.                                                   |
| Riboflavin-containing glutathione reductase | Catalyzes the conversion of oxidized glutathione (glutathione disulfide; GSSG) to its reduced form. |
| GSH transferase isoenzymes           | Conjugation of GSH with fat-soluble substances for liver detoxification and the detoxification of environmental carcinogens, such as those found in tobacco smoke. |
| Selenium-containing glutathione peroxidase (GPX) | Protects cells from hydrogen peroxides and lipid hydroperoxides. |
| Leukotriene C_4 synthase             | Conjugation of leukotriene A_4 with GSH, resulting in the generation of leukotrienes C_4. Gamma-glutamyl transpeptidase then metabolizes leukotrienes C_4 to leukotrienes D_4. |
A total of 12 reports were screened (9,10,17,19–27). Only one report was excluded because it involved the use of inhaled GSH in sheep (17). In total, 11 articles were found to meet the inclusion criteria and were included in this review (9,10,19–27). Table 3 displays the characteristics of the studies included in this review.

**Discussion**

Based exclusively on the published evidence included in this review, inhaled GSH is potentially indicated for the following clinical conditions: cystic fibrosis (CF), chronic otitis media with effusion (OME), HIV seropositive individuals, idiopathic pulmonary fibrosis (IPF) and chronic rhinitis. These conditions were chosen since the published studies were of good quality, received A and B evidence grades, and their respective results demonstrated benefits from the use of GSH inhalation.

Inhaled GSH cannot be recommended as a potential treatment for emphysema since the quality of evidence is lacking at the present time. The emphysema case report had notable limitations since serial spirometry was not documented, and the placebo effect could not be ruled-out (22). However, this does not necessarily indicate that GSH inhalation would be of no benefit for emphysema patients. There is experimental and human data demonstrating a link between GSH, oxidant-derived damage and possible protection against the development of emphysema. An in vitro study demonstrated that GSH could retard the oxidant-mediated down-regulation of α-1-proteinase inhibitor activity in smokers’ emphysema (28). This finding is important since one of the principal pathophysiological mechanisms of emphysema is the down-regulation of this enzyme by means of oxidative damage (29). Moreover, in a recent review of lung GSH and cigarette smoke-induced airway disease, increased GSH in the ELF of chronic smokers was presumed to be a protective adaptive mechanism against the development of chronic obstructive pulmonary disease (COPD) (30). Considering that not all chronic smokers go on to develop COPD, the authors in that review pointed out that genetic variations in the molecular mechanisms that regulate GSH metabolism might explain why some individuals are better protected against the development of COPD. It thus appears that emphysema patients are subjected to progressive tissue damage due, in part, to the consequences of GSH deficiency and/or genetic variations in GSH metabolism. Since GSH inhalation would presumably offer both antioxidant protection and GSH replenishment, this method of treatment would potentially benefit emphysema patients.

Asthma is another condition where inhaled GSH cannot be recommended since this treatment caused notable side effects (e.g. breathlessness, bronchoconstriction and cough) in the cited study (21). These side effects were linked primarily to the production of sulfites that occurred when GSH was in solution. GSH inhalation should continue to be explored as a potential treatment for asthma. None of the asthma patients in the study had their urine tested for sulfites. A positive test for sulfites would have eliminated these patients from entering the study. Accordingly, the results might have been much more favorable if patients without sulfite sensitivities were included.

This issue of asthma and sulfite sensitivities is an important one for clinicians to be mindful of. Sulfites are found in beer, wine, restaurant salad bars, seafood, potatoes, processed foods and many pharmaceuticals (31). Many asthma patients report being sensitive to sulfites. In an Australian study, ~30% of asthmatic patients reported being sensitive to sulfites in wine (32). A more recent and rigorous scientific study, however, demonstrated that asthma patients can tolerate varying amounts of sulfites in wines ranging from 20, 75 or 150 parts per million (ppm) (33). Only a small minority of patients in this study (4 of 24 self-reported wine-sensitive asthmatics) exhibited reactions when challenged with 300 ppm of sulfites. One report indicated that 4–8% of asthmatics are sensitive to sulfites (34). Other reports have estimated the incidence of sulfite sensitivity to be around 5–11% (35,36). Even though the exact percentage of sulfite-sensitive asthmatics is difficult to ascertain, sulfite sensitivity is an important factor to assess when using or evaluating research done on inhaled GSH.

**Future Research Directions**

There are additional clinical conditions that might benefit from this type of treatment, but further studies are necessary. One such condition is Farmer’s lung (FL), which is a hypersensitivity pneumonitis caused by the inhalation of thermophilic actinomycetes and spores of *Aspergillus* specie (11). A study was undertaken to investigate the effect of pulmonary GSH levels after hay exposure in patients with FL and in asymptomatic farmers (AF) (11). Fifteen symptomatic patients with FL...
Table 3. Summary of articles demonstrating the effectiveness of inhaled glutathione for the treatment of pulmonary diseases and respiratory-related conditions

| Reference | Condition                                      | N Description                                                                 | Dosages of inhaled GSH                                                                 | Outcome                                                                 | Evidence grade                                      |
|-----------|------------------------------------------------|--------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|-----------------------------------------------------------------------|---------------------------------------------------|
| (21)      | Asthma                                         | Eight asthma patients [mean age, 29 ± 7 (standard deviation; SD) years]        | 600 mg once weekly for 3 months                                                      | A subset of patients with clinically stable mild asthma experienced a bronchoconstrictor effect when treated with inhaled GSH. | A: Randomized placebo-controlled trial            |
| (23)      | Chronic otitis media with effusion (chronic OME) | 30 patients (3–12 years of age; mean age, 5.8 years) and 30 controls (3–12 years of age; mean age, 6.1 years) | 600 mg of GSH in 4 ml of saline subdivided into five 2-min sessions by nasal aerosol every 3–4 waking h for 2 weeks | GSH should be considered for the nonsurgical management of chronic OME. | A: Randomized placebo-controlled trial            |
| (24)      | Cystic fibrosis (CF)                           | Nine patients [mean age, 16.1 ± 1.44 (SD) years] received the S-nitrosoglutathione (GSNO) and 11 patients [mean age, 19.9 ± 3.45 (SD) years] received the phosphate-buffered saline (PBS) solution | 0.05 ml/kg of 10 mM GSNO                                                              | The treatment group showed a modest improvement in oxygenation that was thought to be independent of the physiological effects of nitric oxide. | A: Randomized placebo-controlled trial            |
| (27)      | CF                                             | 19 patients (6–19 years of age) were randomized to treatment [mean age, 13.3 ± 4.1 (SD) years] or placebo groups [mean age, 12.9 ± 4.9 (SD) years] | Total daily dose administered to the patients in the treatment group was 66 mg/kg of body weight | GSH can improve clinical parameters in CF patients, and that effective treatment should include the correction of GSH deficiency. | A: Randomized placebo-controlled trial            |
| (9)       | Idiopathic pulmonary fibrosis (IPF)            | 10 patients with IPF [mean age, 46 ± 3 (SD) years] and 19 normal nonsmokers [mean age, 36 ± 3 (SD) years] | 600 mg twice daily for 3 days                                                       | Inhaled GSH might be beneficial among IPF patients by reversing the oxidant-antioxidant imbalance. | B: Nonrandomized controlled trial                 |
| (19)      | Human immunodeficiency virus (HIV) seropositive individuals | 14 HIV seropositive individuals [mean age, 32 ± 2 (SD) years] | 600 mg twice daily for 3 days                                                        | It is a reasonable therapeutic strategy to augment the deficient GSH levels of the lower respiratory tracts of HIV seropositive individuals. | B: Cohort ‘outcomes’ research                      |
| (20)      | Chronic rhinitis                               | 13 patients with chronic rhinitis and 13 healthy subjects (4–15 years of age for all subjects; mean age, 8.2 years) | 600 mg daily for 14 days                                                              | Statistically significant improvement in nasal obstruction, rhinorrhea and ear fullness. | B: Nonrandomized controlled trial                 |
| (10)      | CF                                             | Seven CF patients [mean age, 25 ± 1 (SD) years]                                | 600 mg of GSH for 3 days                                                            | Inhalation therapy with GSH does normalize the respiratory epithelial surface oxidant-antioxidant balance in CF patients. | B: Cohort ‘outcomes’ research                      |
| (25)      | CF                                             | 21 patients with CF (16–37 years of age for all subjects) | 300 or 450 mg three times daily for 14 days                                         | Inhaled GSH can permeate the lower airways of the lungs and improve important parameters of lung function in CF patients despite not having any effect upon markers of oxidative injury. | B: Cohort ‘outcomes’ research                      |

(continued)
[mean age, 42 ± 1 (SD) year] were compared with 10 AF [mean age, 43 ± 1 (SD) year] serving as the control group. All patients had baseline lung function testing and testing at various time intervals following hay exposures. The authors of this study concluded that FL and AF patients have characteristically different intrapulmonary levels of GSH, and that the pathogenesis of FL is likely related to GSH regulatory mechanisms. They also speculated that AF patients have a better ability to upregulate their pulmonary GSH levels, which would protect them against active disease. Clinical testing of inhaled GSH in patients with FL is warranted.

The administration of GSH inhalation before and/or immediately following exercise is another potential application of this novel treatment. Exercise is a known inducer of oxidative stress leading to free radical production, which can encourage lipid peroxidation and tissue damage among individuals with deficient and/or impaired antioxidant systems. As stated in the beginning of this report, selenium is a cofactor in the GPX enzyme that protects cells from hydrogen peroxides and lipid hydroperoxides. When under situations of oxidative stress, the GPX enzyme will markedly increase in the lungs as an antioxidant adaptive response (37). By supplying more GSH to the lung tissues, more of this enzyme might be available to help reduce the production of free radicals associated with exercise. Although these assumptions are very speculative, it does seem possible and even logical that GSH inhalation would benefit those who regularly exercise by increasing exercise tolerance, and by maintaining and/or replenishing the antioxidant systems within the lungs.

Multiple chemical sensitivity disorder (MCSD) is another condition that might be clinically responsive to this treatment. Patients with this disorder are known to have bronchial hyperreactivity and even exhibit asthma-like symptoms (38). Unlike asthma, MCSD is not associated with atopy and immunoglobulin E (IgE)-mediated allergic mechanisms (39). The prevailing theory explaining the cause of MCSD is a fusion between two separate theories—the neural sensitization and nitric oxide/peroxynitrite theories (40). This fusion theory, proposed by Pall, links long term potentiation of N-methyl-d-aspartate (NMDA) receptors at the synapses of nerve cells by glutamate and aspartate to an increased production of nitric oxide and its oxidant product, peroxynitrite (40,41). Treatment with antioxidants may improve symptoms of MCSD by reducing the peroxynitrite elevations and other biochemical dysfunctions that are associated with such elevations (40,41). Glutathione inhalation may be ideal since the primary route by which patients with MCSD get triggered is through smelling and breathing. Sulfite sensitivity would have to be considered since inhaled GSH could provoke adverse events. This treatment might be capable of providing antioxidant protection to both the upper and lower respiratory airways, which would theoretically help to reduce the symptoms of MCSD and the production of peroxynitrite. More research studies are necessary.

Two final conditions, cigarette smoking and lung cancer, are worth mentioning since they are intimately related to each other and are affected by GSH and its related enzymes. These conditions are influenced by the glutathione S-transferase (GST) group of enzymes that are found in significant quantities in the bronchioles and alveoli of the lungs (42), and in very high concentrations in the bronchial epithelium (43). Among smokers, a lack of the GST mu enzyme was thought to be associated with a greater risk of lung cancer, especially if there was a cancer and/or lung cancer history among the relatives of the patients in this study (44). Since the GST mu enzyme detoxify carcinogens in tobacco, any deficiency of this enzyme was presumed to be associated with an increased risk of lung cancer. However, a more recent study pertaining to the GST group of enzymes found no such association (45). In this meta-analysis, polymorphisms in the GST genes had no associations or weakly positive associations with risk factors for lung cancer. Despite the
need for more research, GSH inhalation might be beneficial for smokers to augment their GST enzymes, which would help facilitate the detoxification of carcinogens. Even though the best intervention for these patients would be smoking cessation, many patients lack the necessary willpower to quit. For these patients, regular GSH inhalation might reduce oxidants generated from cigarette smoke (~10^14 free radicals/puff) (46), and the epithelial lung injury associated with smoking (47).

For lung cancer patients, the use of GSH inhalation is not recommended. Cancer cells use multiple mechanisms (e.g., altered transport of a drug, inhibition of drug-induced apoptosis and elevation of cellular GSH) to circumvent the cytotoxic effects of chemotherapeutic agents (48). Early research studies showed that GSH was able to reduce cytotoxicity to chemotherapeutic compounds by boosting the metabolism of drugs to less active compounds, or by the detoxification of free radicals (49,50). More recently, research has revealed that the levels of a specific GST enzyme increases among cancer cells with higher differentiation grades, and that these drug-resistant gene products are found in lung carcinomas at the time of surgical resection (51). There is also speculation that GSH might be capable of repairing drug-induced injury at the DNA level (48). A recent review article has described the involvement of glutathione in the detoxification or inactivation of platinum drugs—the most commonly employed drugs for the treatment of advanced stage lung cancer patients (52). Based on this information, it would be unwise and illogical to use GSH inhalation while lung cancer patients are undergoing active chemotherapy treatment.

**Mechanism of Action**

Inhalation of GSH results in a mechanism of action confined to the upper airways and lungs (Fig. 1), and will not influence plasma levels to a significant degree. In the studies that measured both lung and plasma levels of GSH, the plasma levels remained essentially unchanged following GSH inhalation. Seven of the studies included in this review demonstrated that GSH inhalation exerts its effects upon the lower respiratory tract (9,10,19,24–27). The upper respiratory tract also appears to benefit from GSH augmentation. Two studies involving patients with upper respiratory tract diseases showed clinical benefits from GSH inhalation treatment (20,23). The predominant mechanism responsible for GSH’s therapeutic effects are probably related to its antioxidant properties that offer protection against oxidative injury, and/or assist with the normalization of the oxidant–antioxidant balance within the upper and lower respiratory tract. Even though the majority of these studies suggested that antioxidant protection was the principal reason for the favorable treatment responses, some of the studies were unable to demonstrate a change in markers of oxidation from this treatment. More data is necessary to confirm the precise nature of GSH’s antioxidant properties within the upper and lower respiratory tract. Additional explanations for GSH’s therapeutic effects might include an improvement in host defenses (e.g., increased cytotoxic lymphocytes), and better oxygenation (e.g., an increase in oxygen saturation). GSH inhalation produced clinically meaningful results in the majority of diseases that were studied. Specifically, GSH inhalation was shown to improve clinical markers of respiratory function that inevitably impact upon quality of life and disease progression. These improvements were the most important outcomes and features of this novel treatment.

**Considerations Prior to Initiating GSH Inhalation**

The urine should be tested for sulfite sensitivity. A special test strip can be dipped in the urine, and is known as the ‘EM-Quant 10013 Sulfite Test.’ It can be easily located through any search engine on the Internet (53). Even though instructions for sulfite testing have been published elsewhere (54), a brief description of the procedure is outlined below:

A random (fresh) urine sample is suitable, but a first morning void may be preferable due to its higher concentration. Once the test strip is dipped in the urine (for 1 s), the reaction zone changes color to indicate the concentration of sulfites present. After 30 s, the color on the test strip is compared to a color scale on the bottle indicating the concentrations of sulfites in the urine (can detect 10, 40, 80, 180 and 400 ppm of sulfites). The resultant concentration should be multiplied by a factor of 1.5 to provide the amount of free sulfites in mg/l (ppm). The strip will not detect below 10 ppm. The urine samples should be preservative free, and the urinary pH should also be tested with pH paper. If the urine pH is below 6, then the amount of sulfites might be underestimated by the test. In such cases, consider adding sodium acetate or sodium hydroxide to raise the pH to at least 7–10 (should not exceed a pH of 12), and then repeat with a new test strip.

If the urine test were positive for sulfites (normally they are absent), the use of inhaled GSH would be strictly contraindicated.

**Method of Delivery, Recommended Daily Dosages and Side Effects**

With a nebulizer, a solution of GSH is made into an aerosol and is delivered to the upper respiratory tract and the lungs through a mask that covers the nose and mouth, or is delivered directly into the lungs via a mouthpiece. Any compounding pharmacist would be
able to prepare the solution of GSH at the desired concentrations. The typical dosages used in the studies cited in Table 3 were 600 mg once daily, 600 mg twice daily, 900 mg daily, 1350 mg daily or a daily dose of 66 mg/kg of body weight. Better results are more likely to be achieved with doses of at least 600 mg or more each day. One of the studies used much larger doses (66 mg/kg of body weight) since the authors speculated that these would be necessary to replace half of the amount of GSH that is produced each day (e.g. a 150 lb male synthesizes 10 g daily and would need 5 g as a replacement dose) (27). When patients are unresponsive to doses in the range of 600–1350 mg per day, it might be suitable to try doses that would replace half the estimated amount of GSH that is synthesized each day. These gram doses might yield better clinical results.

In terms of side effects, GSH inhalation is very safe. Minor side effects such as mild coughing and an unpleasant odor were reported in some of the studies included in this review. These minor side effects, better described as mild nuisance problems, were not severe enough to cause any of the study participants to discontinue treatment with inhaled GSH. The only worrisome or potentially life-threatening side effect to note is bronchoconstriction, which would be more likely to occur among sulfite-sensitive asthma and MCSD patients. However, if proper precautions such as sulfite testing are done prior to treatment, this serious side effect should be avoidable.

**Monitoring the Clinical Response to Inhaled GSH**

For pulmonary diseases or respiratory-related conditions, baseline pulmonary function testing with a spirometer or a simple peak flow meter is recommended prior to the
first treatment. After a prescribed period of treatment time, pulmonary function tests should be repeated. This will help to establish if there are any clinical improvements from regular GSH inhalation.

Conclusions

GSH inhalation is an effective treatment for a variety of pulmonary diseases and respiratory-related conditions. Even very serious and difficult-to-treat diseases (e.g., CF, IPF) yielded benefits from this novel treatment. GSH inhalation is very safe, and rarely causes major or life-threatening side effects. The potential applications are numerous when one considers just how many pulmonary diseases and respiratory-related conditions are affected by deficient antioxidant status, poor oxygenation and/or impaired host defenses. More studies are clearly warranted.

Acknowledgments

The author would like to thank Mr. Glen Carr and Mr. Andrew Dick for their wonderful illustration of GSH’s mechanism of action.

References

1. Groff JL, Gropper SS, Hunt SM. Advanced Nutrition and Human Metabolism, 2nd edn. St. Paul, MN: West Publishing Company, 1995, 165–6.
2. Bhagavan NV. Medical Biochemistry. Boston, MA: Jones and Barlett, 1992, 323–4.
3. Kidd PM. Glutathione: systemic protectant against oxidative and free radical damage. Altern Med Rev 1997;2:155–76.
4. Tare SS, Meister A. Gamma-glutamyl transpeptidase: catalytic, structural and functional aspects. Mol Cell Biochem 1981;39:357–68.
5. Yoshimoto T, Soberman RJ, Spur B, Austen KV. Properties of highly purified leukothriene C4 synthase of guinea pig lung. J Clin Invest 1988;81:866–71.
6. Lomaestro B, Malone M. Glutathione in health and disease: pharmacotherapeutic issues. Ann Pharmacother 1995;29:1263–73.
7. Cantin AM, North SL, Hubbard RC, Crystal RG. Normal alveolar epithelial lining fluid contains high levels of glutathione. J Appl Physiol 1987;63:152–7.
8. Rahman I, MacNee W. Oxidative stress and regulation of glutathione in lung inflammation. Eur Respir J 2000;16:534–54.
9. Buhl R, Vogelmeier C, Critenden M, Hubbard RC, Hoyt RF Jr, Wilson EM, et al. Augmentation of glutathione in the fluid lining the epithelium of the lower respiratory tract by directly administering glutathione aerosol. Proc Natl Acad Sci USA 1990;87:4063–67.
10. Centre for Evidence-Based Medicine: <http://www.cebm.net/levels_ofvidence.asp#levels> 2006.
11. Holroyd KJ, Buhl R, Borok Z, Roum JH, Bokser AD, Grimes GJ, et al. Correction of glutathione deficiency in lower respiratory tract of HIV seropositive individuals by glutathione aerosol treatment. Thorax 1993;48:985–9.
12. Testa B, Mesolella M, Testa D, Giuliano A, Costa G, Maione F, et al. Glutathione in the upper respiratory tract. Ann Otol Rhinol Laryngol 1995;104:117–9.
13. Martareis RM, Roca J, Barberá JA, de Jover L, MacNee W, Rodriguez- Roisin R. Nebulized glutathione induces bronchoconstriction in patients with mild asthma. Am J Respir Crit Care Med 1997;156:425–30.
14. Lamson DW, Brignall MS. The use of nebulized glutathione in the treatment of emphysema: a case report. Altern Med Rev 2000;5:429–31.
15. Witschi A, Reddy S, Stofer B, Lauterburg BH. The systemic availability of oral glutathione. Eur J Clin Pharmacol 1992;43:667–9.
40. Pall ML. Multiple chemical sensitivity – the end of controversy. <http://molecular.biosciences.wsu.edu/faculty/pall/pall_mcs.htm> 2006.

41. Pall ML. Elevated nitric oxide/peroxynitrite theory of multiple chemical sensitivity: central role of N-methyl-D-aspartate receptors in the sensitivity mechanism. Environ Health Perspect 2003;111:1461–4.

42. Awasthi YC, Singh SV, Ahmad H, Moller PC. Immunohistochemical evidence for the expression of GST1, GST2, and GST3 gene loci for glutathione S-transferase in human lung. Lung 1987;165:323–32.

43. Anttila S, Hirvonen A, Vainio H, Husgaufel-Pursiainen K, Hayes JD, Ketterer B. Immunohistochemical localization of glutathione S-transferase in human lung. Cancer Res 1993;53:5643–8.

44. Cerrahoglu K, Kunter E, Isitmangil T, Oztosun AI, Isitmangil G, Okutan O, et al. Can’t lung cancer patients detoxify procarcinogens? Allerg Immunol 2002;34:51–5.

45. Ye Z, Song H, Higgins JPT, Pharoah P, Danesh J. Five glutathione S-transferase gene variants in 23,452 cases of lung cancer and 30,397 controls: meta-analysis of 130 studies. PloS Med 2006;3:e91.

46. Nakayama T, Churh DF, Pryor W. Quantitative analysis of the hydrogen peroxide formed in aqueous cigarette tar extracts. Free Radic Biol Med 1989;7:9–15.

47. Lannan S, Donaldson K, Brown D, MacNee W. Effect of cigarette smoke and its condensates on alveolar epithelial cell injury in vitro. Am J Physiol 1994;266:L92–L100.

48. Iqbal MP. Mechanisms of drug resistance in cancer cells. Pak J Med Sci 2003;19:118–27.

49. Arrick BA, Nathan CF. Glutathione metabolism as a determinant of therapeutic efficacy: a review. Cancer Res 1984;44:4224–32.

50. Meister A. Selective modification of glutathione metabolism. Science 1983;220:472–7.

51. Mattern J, Koomägi R, Volm M. Expression of drug resistance gene products during progression of lung carcinomas. Oncol Rep 2002;9:1181–4.

52. Yang P, Ebbert JO, Sun Z, Weinshilboum RM. Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: a review. J Clin Oncol 2006;24:1761–9.

53. EM-Quant 10013 Sulfite Test. <http://www.galladechem.com/catalog/test_strips/sulfite-test-strips-10-400-ppm-em-quant–1-pk-of-100.htm> 2007.

54. Wright J, Littleton K. Defects in sulphur metabolism. Int Clin Nut Rev 1989;9:118–9.

Received December 22, 2006; accepted February 13, 2007